ASCO-SITC 2020 — Metastatic RCC: combining ilixadencel with sunitinib improves responses


  • Pavankumar Kamat
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Addition of intratumoral ilixadencel to sunitinib improved responses in patients with newly diagnosed synchronous metastatic renal cell carcinoma (RCC).

Why this matters

  • Ilixadencel is an off-the-shelf dendritic cell-based primer, designed to elicit an anticancer immune response when injected intratumorally. 
  • This phase 2 study investigated its potential as first-line systemic therapy for newly diagnosed synchronous metastatic RCC. 

Study design

  • Phase 2 MERECA trial evaluated patients who were randomly assigned to receive either intratumoral ilixadencel pre-nephrectomy followed by sunitinib post-nephrectomy (n=45) or sunitinib monotherapy post-nephrectomy (n=25).
  • Funding: Immunicum AB.

Key results

  • The complete response rate was 11% with ilixadencel plus sunitinib and 4% with sunitinib monotherapy.
  • The confirmed overall response rate was 42.2% in patients treated with ilixadencel plus sunitinib and 24.0% in patients treated with sunitinib monotherapy.
  • The median duration of response for the ilixadencel plus sunitinib group and the sunitinib monotherapy group was 7.1 and 2.9 months, respectively. 
  • The median progression-free survival for the ilixadencel plus sunitinib group and the sunitinib monotherapy group was 11.8 and 11.0 months, respectively. 
  • Ilixadencel did not add any treatment-related grade 3-4 adverse events or serious adverse events; pyrexia was the most common adverse event related to ilixadencel treatment.

Limitations

  • Small sample size. 
  • Short follow-up duration.

Expert commentary
Dr Magnus Lindskog, MD, PhD, from the Uppsala University Hospital, Sweden commented: "The observed activity of ilixadencel appears to be driven by responses in patients with intermediate risk."